Inhibition of STAT signalling in bladder cancer by diindolylmethane - relevance to cell adhesion, migration and proliferation

Current Cancer Drug Targets

Volumn 13, Issue 1, 2013, Pages 57-68

  Sun, Yiyang ^a,c   Cheng, Mai Kim ^a   Griffiths, Thomas R L ^b   Mellon, J Kilian ^a,b   Kai, Bao ^a,d   Kriajevska, Marina ^a   Manson, Margaret M ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b LEICESTER GENERAL HOSPITAL   (United Kingdom)

^c Novartis Pharmaceuticals UK Limited   (United Kingdom)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Adhesion; Bladder cancer; Diindolylmethane; Migration; Prevention; STAT

Indexed keywords

3, 3' DIINDOLYLMETHANE; 4 (1 AMINOETHYL) N (4 PYRIDYL) CYCLOHEXANECARBOXAMIDE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL) PYRAZOLO [3, 4 D] PYRIMIDINE; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; N BENZYL 2 CYANO 3 (3, 4 DIHYDROXYPHENYL) ACRYLAMIDE; POLO LIKE KINASE 1; SARACATINIB; SMALL INTERFERING RNA; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; SURVIVIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BLADDER CANCER; CELL ADHESION; CELL CYCLE ARREST; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ELECTROPORATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; REPORTER GENE; WESTERN BLOTTING;

EID: 84875867239     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800913804486610     Document Type: Article

References (56)

1. Darnell, J. E. Validating Stat3 in cancer therapy. Nature Med. 2005, 11, 595-596.
2. Yu, H.; Jove, R. The STATs of cancer-new molecular targets come of age. Nature Rev. Cancer 2004, 4, 97-105.
3. Sansone, P.; Bromberg, J. Targeting the interleukin-6/Jak/Stat pathway in human malignancies. J. Clin. Oncol. 2012, 30, 1005-1014.
4. Ma, X. T.; Wang, S.; Ye, Y. J.; Du, R. Y.; Cui, Z. R.; Somsouk, M. Constitutive activation of Stat3 signaling pathway in human colorectal carcinoma. World J. Gastroenterol. 2004, 10, 1569-1573.
5. Yu, H.; Pardoll, D.; Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nature Rev. 2009, 9, 798-809.
6. Chen, H.; Ye, D.; Xie, X.; Chen, B.; Lu, W. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol. Oncol. 2004, 94, 630-635.
7. Calo, V.; Migliavacca, M.; Bazan, V.; Macaluso, M.; Buscemi, M.; Gebbia, N.; Russo, A. STAT proteins: From normal control of cellular events to tumorigenesis. J. Cell Physiol.2003, 197, 157-168.
8. Ni, Z.; Lou, W.; Lee, S. O.; Dhir, R.; DeMiguel, F.; Grandis, J. R.; Gao, A. C. Selective activation of members of the signal transducers and activators of transcription family in prostate carcinoma. J. Urol. 2002, 167, 1859-1862.
9. Li, N.; Grivennikov, S. I.; Karin M. The unholy trinity: Inflammation, cytokines and STAT3 shape the cancer microenvironment. Cancer Cell 2011, 19, 429-431.
10. Kawada, M.; Seno, H.; Uenoyama, Y.; Sawabu, T.; Kanda, N.; Fukui, H.; Shimahara, Y.; Chiba, T. Signal transducers and activators of transcription 3 activation is involved in nuclear accumulation of o-catenin in colorectal cancer. Cancer Res. 2003, 66, 2913-2917.
11. Sultan, A. S.; Xie, J.; LeBaron, M. J.; Ealley, E. L.; Nevalainen, M. T.; Rui, H. Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene 2005, 24, 746-760.
12. Silver, D. L.; Naora, H.; Liu, J.; Cheng, W.; Montell, D. J. Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res. 2004, 64, 3550-3558.
13. Gough, D. J.; Corlett, A.; Schlessinger, K.; Wegrzyn, J.; Larner, A. C.; Levy, D. E. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 2009, 324, 1713-1716.
14. Yang, J.; Stark, G. R. Roles of unphosphorylated STATs in signalling. Cell Res. 2008, 18, 443-451.
15. Ho, P. L.; Lay, E. J.; Jian, W.; Parra, D.; Chan, K. S. Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer. Cancer Res. 2012, 72, 3135-3142.
16. Lin, L.; Hutzen, B.; Li, P-K.; Ball, S.; Zuo, M.; DeAngelis, S.; Foust, E.; Sobo, M.; Friedman, L.; Bhasin, D.; Cen, L.; Li, C.; Lin, J. A. novel small molecule, LLL12, inhibits STAT phosphorylation and activities and exhibits potent growth suppressive activity in human cancer cells. Neoplasia 2010, 12, 39-50.
17. Yu, Z-Y.; Huang, R.; Xiao, H.; Sun, W-F.; Shan, Y-J.; Wang, B.; Zhao, T-T.; Ding, B.; Zhao, Z-H.; Liu, X-L.; Wang, S-Q.; Yang, RF.; Luo, Q-L.; Cong, Y-W. Fluacrypyrim, a novel STAT3 activation inhibitor, induces cell cycle arrest and apoptosis in cancer cells harbouring constitutively active STAT3. Int. J. Cancer 2010, 127, 1259-1270.
18. Yang, F.; Jove, V.; Xin, H.; Hedvat, M.; Van Meter, T. E.; Yu, H. Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT Signalling pathways. Mol. Cancer Res. 2010, 8, 35-45.
19. Sarkar, H.; Li, Y. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res. 2006, 66, 3347-3350.
20. Howells, L. M.; Moiseeva, E. P.; Neal, C. P.; Foreman, B. E.; Andreadi, C. K.; Sun, Y.; Hudson, A.; Manson, M. M. Predicting the physiological relevance of in vitro cancer preventive activities of phytochemicals. Acta Pharmacol. Sin. 2007, 28, 1274-1304.
21. IARC Workshop. Cruciferous Vegetables, Isothiocyanates and Indoles. IARC Handbooks of Chemoprevention, IARC Press, Lyon, 2004.
22. Li, Y.; Vandenboom, T. G.; Wang, Z.; Kong, D.; Ali, S.; Philip, P. A.; Sarkar, F. H. miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res. 2010, 70, 1486-1495.
23. Bell, M. C.; Crowley-Nowick, P.; Bradlow, H. L.; Sepkovic, D. W.; Schmidt-Grimminger, D.; Howell, P.; Mayeaux, E. J.; Tucker, A.; Turbat-Herrera, E. A.; Mathis, J. M. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol. Oncol. 2000, 78, 123-129.
24. Rosen, C. A.; Bryson, P. C. Indole-3-carbinol for recurrent respiratory papillomatosis: long-term results. J. Voice 2004, 18, 248-53.
25. Del Priore, G.; Gudipudi, D. K.; Montemarano, N.; Restivo, A. M.; Malanowska-Stega, J.; Arslan, A. A. Oral diindolylmethane (DIM): Pilot evaluation of a non-surgical treatment for cervical dysplasia. Gyn. Oncol. 2010, 116, 464-467.
26. Lian, J. P.; Word, B.; Taylor, S.; Hammons, G. J.; Lyn-Cook, B. D. Modulation of the constitutive activated STAT3 transcription factor in pancreatic cancer prevention: Effects of indole-3-carbinol (I3C) and genistein. Anticancer Res. 2004, 24, 133-137.
27. Moneef, M. A.; Sherwood, B. T.; Bowman, K. J.; Kockelbergh, R. C.; Symonds, R. P.; Steward, W. P.; Mellon, J. K.; Jones, G. D. Measurements using the alkaline comet assay predict bladder cancer cell radiosensitivity. Brit. J. Cancer 2003, 89, 2271-2276.
28. Akiyama, S. K.; Yamada, S. S.; Chen, W. T.; Yamada, K. M. Analysis of fibronectin receptor function with monoclonal antibodies: Roles in cell adhesion, migration, matrix assembly, and cytoskeletal organization. J. Cell Biol. 1989, 109, 863-875.
29. Schreiber, E.; Matthias, P.; Mu{double acute}ller, M. M.; Schaffner, W. Rapid detection of octamer binding proteins with 'mini-extracts' prepared from a small number of cells. Nucleic Acids Res. 1989, 17, 6419.
30. Beadling, C.; Ng, J.; Babbage, J. W.; Cantrell, D. A. Interleukin-2 activation of STAT5 requires the convergent action of tyrosine kinases and a serine/threonine kinase pathway distinct from the Raf1/ERK2 MAP kinase pathway. EMBO J. 1996, 15, 1902-1913.
31. Bromberg, J. F.; Wrzeszczynska, M. H.; Devgan, G.; Zhao, Y.; Pestell, R. G.; Albanese, C.; Darnell, J. E. STAT3 as an oncogene. Cell 1999, 98, 295-303.
32. Howells, L. M.; Mitra, A.; Manson, M. M. Comparison of oxaliplatin-and curcumin-mediated anti-proliferative effects in colorectal cell lines. Int. J. Cancer 2007, 121, 175-183.
33. Baumgar, E.; Cohen, M. S.; Neto, B. S.; Jacobs, M. A.; Wotkowicz, C.; Rieger-Christ, K. M.; Biolo, A.; Zeheb, R.; Loda, M.; Libertino, J. A.; Summerhayes, I. C. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin. Cancer Res. 2007, 13, 1685-1694.
34. Brew, C. T.; Aronchik, I.; Kosco, K.; McCammon, J.; Bjeldanes, L. F.; Firestone, G. L. Indole-3-carbinol inhibits MDA-MB-231 breast cancer cell motility and induces stress fibres and focal adhesion formation by activation of Rho kinase activity. Int. J. Cancer 2000, 124, 2294-2302.
35. Chen, C-L.; Cen, L.; Kohout, J.; Hutzen, B.; Chan, C.; Hsieh, F-C.; Loy, A.; Huang, V.; Cheng, G.; Lin, J. Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol. Cancer 2008, 7, 78.
36. Chan, K. S.; Espinosa, I.; Chao, M.; Wong, D.; Ailles, L.; Diehn, M.; Gill, H.; Presti, J.; Chang, H. Y.; van de Rijn, M.; Shortliffe, L.; Weissman, I. L. Identification, molecular characterization, clinical prognosis and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl. Acad. Sci.U.S.A. 2009, 106, 14016-14021.
37. Azare, J.; Leslie, K.; Al-Ahmadie, H.; Gerald, W.; Weinreb, P. H.; Violette, S. M.; Bromberg, J. Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6. Mol. Cell Biol. 2007, 27, 4444-4453.
38. Zhang, C. H.; Xu, G. L.; Jia, W. D.; Li, J. S.; Ma, J. L.; Ren, W. H.; Ge, Y. S.; Yu, J. H.; Liu, W. B.; Wang, W. Activation of STAT3 signal pathway correlates with twist and E-cadherin expression in hepatocellular carcinoma and their clinical significance. J. Surg. Res. 2012, 174, 120-129.
39. Xiong, H.; Hong, J.; Du, W.; Lin, Y. W.; Ren, L. L.; Wang, Y. C.; Su, W. Y.; Wang, J. L.; Cui, Y.; Wang, Z. H.; Fang, J. Y. Roles of STAT3 and ZEB1 proteins in E-cadherin downregulation and human colorectal cancer epithelial-mesenchymal transition. J. Biol. Chem. 2012, 287, 5819-5832.
40. Mejlvang, J.; Kriajevska, M.; Vandewalle, C.; Chernova, T.; Sayan, A. E.; Berx, G.; Mellon, J. K.; Tulchinsky, E. Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. Mol. Biol. Cell 2007, 18, 4615-4624.
41. Sun, Y. STATs signalling in human bladder cancer:potential chemopreventive role for indoles. PhD Thesis 2007; University of Leicester, UK.
42. Chaturvedi, P.; Reddy, M. V.; Reddy, E. P. Src kinases and not JAKs activate STATs during IL-3 induced myeloid cell proliferation. Oncogene 1998, 16, 1749-1758.
43. Su, L.; David, M. Distinct mechanisms of STAT phosphorylation via the interferon-alpha/beta receptor: selective inhibition of STAT3 and STAT5 by piceatannol. J. Biol. Chem. 2000, 275, 12661-12666.
44. Kandala, P. K.; Srivastava, S. K. Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting signal transducer and activator of transcription 3 (STAT3). BMC Med. 2012, 10, 9.
45. Li, L.; Shaw, P. Elevated activity of STAT3C due to higher DNA binding affinity of phosphotyrosine dimer rather than covalent dimer formation. J. Biol. Chem. 2006, 28, 33172-33181.
46. Itoh, M.; Murata, T.; Suzuk, M.; Shindoh, M.; Nakajima, K.; Imai, K.; Yoshida, K. Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene 2006, 25, 1195-1204.
47. Debidda, M.; Wang, L.; Zang, H.; Poli, V.; Zheng, Y. A role for STAT3 in Rho GTPase-regulated cell migration and proliferation. J. Biol. Chem. 2005, 280, 17275-17285.
48. Teng, T. S.; Lin, B.; Manser, E.; Ng, D. C. H.; Cao, X. STAT3 promotes directional cell migration by regulating Rac1 activity via its activator-PIX. J. Cell Sci. 2009, 122, 4150-4159.
49. van Rheenan, J.; Condeelis, J.; Glogauer, M. A common cofilin activity cycle in invasive tumor cells and inflammatory cells. J. Cell Sci. 2009, 122, 305-311.
50. Han, L.; Stope, M. B.; de Jesus, M. L.; Weernink, P. A. O.; Urban, M.; Wieland, T.; Rosskopf, D.; Mizuno, K.; Jakobs, K. H.; Schmidt, M. Direct stimulation of receptor-controlled phospholipase D1 by phospho-cofilin. EMBO J. 2007, 26, 4189-4202.
51. Kamai, T.; Tsujii, T.; Arai, K.; Takagi, K.; Asami, H.; Ito, Y.; Oshima, H. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin. Cancer Res. 2003, 9, 2632-2641.
52. Aznar, S.; Valeron, P. F.; del Rincon, S. V.; Perez, L. F.; Perona, R.; Lacal, J. C. Simultaneous tyrosine and serine phosphorylation of STAT3 transcription factor is involved in Rho A GTPase oncogenic transformation. Mol. Biol. Cell 2001, 12, 3282-3294.
53. Lim, K-H.; Baines, A. T.; Fiordalisi, J. J.; Shipitsin, M.; Feig, L. A.; Cox, A. D.; Der, C. J.; Counter, C. M. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell 2005, 7, 533-545.
54. Gildea, J. J.; Harding, M. A.; Seraj, M. J.; Gulding, K.M.; Theodorescu, D. The role of RalA in epidermal growth factor receptor-regulated cell motility. Cancer Res. 2002, 62, 982-985.
55. Tyagi, A.; Agarwal, C.; Harrison, G.; Glode, L. M.; Agarwal, R. Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis 2004, 25, 1711-1720.
56. Rahman, K. M. W.; Li, Y.; Wang, Z.; Sarkar, S. H.; Sarkar, F. H. Gene expression profiling revealed survivin as a target of 3,3'-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res. 2006, 66, 4952-4960.